Introduction: The local application of simvastatin in bone defects was found to enhance new bone formation as it up regulates BMP-2. Unfortunately it also results in local inflammation which is dose and carrier dependent.Aim of the study: The aim of this study was to evaluate available bone quality and quantity after performing maxillary sinus lift with simvastatin /β-TCP combination as bone filling material versus β-TCP alone.Materials and Methods: Open sinus lift was performed to 10 patients (total of 12 sinuses) after evaluating the available bone using CBCT. The sinuses were filled with a either a combination of Simvastatin & β-TCP (Simvastatin group) or β-TCP (β- TCP group. Postoperative CBCT was performed after 1 week and 6 months to evaluate the changes in bone height. In addition to the radiographic evaluation, histological analysis of core biopsies were also performed to evaluate the quantity of newly formed bone. Implant site preparation and implant insertion was performed at this stage.Findings: Clinical findings: No signs of infection or inflammation were recorded during recovery.The histomorphometric results: The amount of newly formed bone was higher in the simvastatin group when compared to the β-TCP group 6 months after the surgery; the difference between the two groups was statistically significant.The radiographic evaluation: The rate of resorption of the simvastatin group was found to be higher than the control group; however the difference between both groups was statistically insignificant.Conclusion: Simvastatin is safe to be used in sinus lift with promising osteoinductive capacity, yet further studies using larger sample size and histological evaluation is needed.